Leerink Partners Maintains a Buy Rating on Health Catalyst (HCAT)

Leerink Partners analyst Stephanie Davis maintained a Buy rating on Health Catalyst (HCAT – Research Report) on September 23. The company’s shares closed last Friday at $53.70. According to TipRanks.com, Davis is More »

Leerink Partners Maintains a Buy Rating on Lantheus (LNTH)

Leerink Partners analyst Richard Newitter maintained a Buy rating on Lantheus (LNTH – Research Report) on September 23. The company’s shares closed last Friday at $26.97, close to its 52-week high of More »